Patents. Law. Pharma.

BLOG

Zachary Silbersher Zachary Silbersher

Can Axsome Therapeutic’s patent-thicket block Apotex’s generic Symbravo?

Axsome Therapeutics sells Symbravo (meloxicam and rizatriptan benzoate) tablets. Apotex has filed an ANDA seeking to distribute a generic version of Symbravo, and in response, Axsome has brought suit under the Hatch-Waxman Act. The rub is that Axsome has listed an enormous number of patents in the Orange Book purportedly covering Symbravo. Can Apotex litigate its way through Axsome’s patent thicket, or will consumers be deprived a lower-cost generic formulation?

Read More
Uncategorized Uncategorized

How did Axsome Therapeutics use its patents to squeeze 14 more years of monopoly pricing for Auvelity?

Axsome Therapeutics stock price rallied this week after the announcement that it had settled its patent lawsuit against Teva.  Sell-side analysts have raised the stock target now that Auvelity’s generic threat has been eliminated.  Under the terms of the settlement, Teva will not enter the market until 2038 or 2039.  Even if other generics emerge, Axsome is likely hampered from offering an earlier date.  This could make Axsome an attractive acquisition target, similar to how Intra-Cellular was recently acquired shortly after settling with a generic for its drug, Capylta.  How did Axsome accomplish such a favorable settlement?  What was Axsome’s patent strategy for Auvelity. 

Read More